Royalty Pharma plc (MUN:RPD)

Royalty Pharma Statistics

Total Valuation

Royalty Pharma has a market cap or net worth of EUR 14.46 billion. The enterprise value is 24.21 billion.

Market Cap	14.46B
Enterprise Value	24.21B

Important Dates

The next estimated earnings date is Wednesday, February 11, 2026.

Earnings Date	Feb 11, 2026
Ex-Dividend Date	Nov 14, 2025

Share Statistics

Current Share Class	427.25M
Shares Outstanding	n/a
Shares Change (YoY)	-3.98%
Shares Change (QoQ)	-0.48%
Owned by Insiders (%)	11.73%
Owned by Institutions (%)	79.02%
Float	374.67M

Valuation Ratios

The trailing PE ratio is 22.18 and the forward PE ratio is 6.39.

PE Ratio	22.18
Forward PE	6.39
PS Ratio	7.22
PB Ratio	1.76
P/TBV Ratio	3.09
P/FCF Ratio	n/a
P/OCF Ratio	7.05
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	37.14
EV / Sales	11.85
EV / EBITDA	n/a
EV / EBIT	17.20
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.48, with a Debt / Equity ratio of 0.93.

Current Ratio	3.48
Quick Ratio	3.47
Debt / Equity	0.93
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	5.59

Financial Efficiency

Return on equity (ROE) is 13.11% and return on invested capital (ROIC) is 5.36%.

Return on Equity (ROE)	13.11%
Return on Assets (ROA)	5.22%
Return on Invested Capital (ROIC)	5.36%
Return on Capital Employed (ROCE)	8.30%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.13
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +37.59% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+37.59%
50-Day Moving Average	32.24
200-Day Moving Average	34.90
Relative Strength Index (RSI)	64.35
Average Volume (20 Days)	216

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.43

Income Statement

In the last 12 months, Royalty Pharma had revenue of EUR 2.00 billion and earned 651.97 million in profits. Earnings per share was 1.49.

Revenue	2.00B
Gross Profit	2.13B
Operating Income	1.33B
Pretax Income	1.11B
Net Income	651.97M
EBITDA	n/a
EBIT	1.33B
Earnings Per Share (EPS)	1.49

Balance Sheet

The company has 813.98 million in cash and 7.64 billion in debt, giving a net cash position of -6.83 billion.

Cash & Cash Equivalents	813.98M
Total Debt	7.64B
Net Cash	-6.83B
Net Cash Per Share	n/a
Equity (Book Value)	8.20B
Book Value Per Share	12.74
Working Capital	1.12B

Cash Flow

Operating Cash Flow	2.05B
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross margin is 106.59%, with operating and profit margins of 66.48% and 32.55%.

Gross Margin	106.59%
Operating Margin	66.48%
Pretax Margin	55.43%
Profit Margin	32.55%
EBITDA Margin	n/a
EBIT Margin	66.48%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 0.78, which amounts to a dividend yield of 2.34%.

Dividend Per Share	0.78
Dividend Yield	2.34%
Dividend Growth (YoY)	0.78%
Years of Dividend Growth	5
Payout Ratio	49.36%
Buyback Yield	3.98%
Shareholder Yield	6.31%
Earnings Yield	4.51%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Royalty Pharma has an Altman Z-Score of 1.49 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.49
Piotroski F-Score	6